| NCT02796755 | Inflammation|Fatigue | Drug: Riluzole|Drug: Placebo | Emory University | Phase 4 | 2016-04-01 | 2016-12-08 |
| NCT00895752 | Fragile X Syndrome | Drug: Riluzole | Indiana University|Indiana Clinical and Translational Sciences Institute | Phase 4 | 2009-04-01 | 2013-04-16 |
| NCT02155829 | PTSD | Drug: Riluzole|Drug: Placebo (for Riluzole) | Uniformed Services University of the Health Sciences|U.S. Army Medical Research and Materiel Command | Phase 1|Phase 2 | 2013-07-01 | 2014-07-21 |
| NCT01204918 | Depression | Drug: Riluzole|Drug: placebo | Yale University | Phase 2 | 2011-06-01 | 2015-02-02 |
| NCT02081027 | Autism Spectrum Disorders | Drug: Riluzole|Drug: placebo | Children's Hospital Medical Center, Cincinnati | Phase 2|Phase 3 | 2013-06-01 | 2016-08-31 |
| NCT01018836 | Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific | Drug: riluzole|Radiation: whole-brain radiation therapy | Rutgers, The State University of New Jersey|National Cancer Institute (NCI) | Phase 1 | 2009-11-01 | 2014-04-30 |
| NCT01303341 | Adult Solid Neoplasm|Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma | Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Riluzole|Drug: Sorafenib Tosylate | National Cancer Institute (NCI) | Phase 1 | 2011-02-01 | 2017-02-06 |
| NCT00523718 | Obsessive-compulsive Disorder|Ocd | Drug: riluzole|Drug: placebo | Yale University | Phase 2 | 2006-09-01 | 2016-05-25 |
| NCT00251303 | Obsessive-Compulsive Disorder|Autism Spectrum Disorder|Autism|Asperger Disorder|Developmental Disorder | Drug: Riluzole|Drug: Placebo | National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC) | Phase 2 | 2005-08-01 | 2014-07-14 |
| NCT01257828 | Cervical Spondylotic Myelopathy | Drug: riluzole|Drug: Placebo medication | AOSpine North America Research Network | Phase 3 | 2011-12-01 | 2016-07-06 |
| NCT02019940 | PTSD | Drug: Riluzole | Yale University|National Center for PTSD | Phase 1 | 2014-01-01 | 2017-02-04 |
| NCT00544544 | Bipolar Depression | Drug: Riluzole | Mclean Hospital | | 2007-06-01 | 2012-03-09 |
| NCT01661855 | Autism Spectrum Disorders | Drug: Riluzole|Drug: Placebo | Evdokia Anagnostou|Holland Bloorview Kids Rehabilitation Hospital|McMaster University|The Hospital for Sick Children|University of Western Ontario, Canada|St. Michael's Hospital, Toronto|University of Toronto|Anagnostou, Evdokia, M.D. | Phase 2 | 2013-09-01 | 2017-03-17 |
| NCT01104649 | Cerebellar Ataxia | Drug: riluzole|Drug: Placebo comparator | S. Andrea Hospital|Agenzia Italiana del Farmaco | Phase 2|Phase 3 | 2010-04-01 | 2015-04-20 |
| NCT00866840 | Melanoma (Skin) | Drug: riluzole | Rutgers, The State University of New Jersey|National Cancer Institute (NCI) | Phase 2 | 2009-04-01 | 2013-11-18 |
| NCT00876889 | Spinal Cord Injury | Drug: Riluzole | The Methodist Hospital System|Christopher Reeve Paralysis Foundation|United States Department of Defense|AO Clinical Investigation and Documentation|Ontario Neurotrauma Foundation | | 2010-04-01 | 2013-07-29 |
| NCT01703039 | Major Depressive Disorder | Drug: Riluzole|Drug: Sertraline|Other: placebo | Brigham and Women's Hospital | Phase 2 | 2013-01-01 | 2016-05-11 |
| NCT00054704 | Bipolar Disorder | Drug: Riluzole|Drug: Placebo | National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC) | Phase 2 | 2003-02-01 | 2016-05-17 |
| NCT03017508 | Social Anxiety Disorder|Performance Anxiety | Drug: BHV-0223|Drug: Placebo | Yale University|Biohaven Pharmaceuticals Inc. | Phase 2|Phase 3 | 2017-01-01 | 2017-01-12 |
| NCT00375050 | Schizophrenia|Schizoaffective | Drug: Riluzole|Drug: Placebo | Yale University|Stanley Medical Research Institute | | 2002-05-01 | 2015-11-16 |
